Get the Stockscreener App
0.5623
0.52%
0.0029
After Hours:
.57
0.0077
+1.37%
Hoth Therapeutics Inc stock is traded at $0.5623, with a volume of 489.05K.
It is up +0.52% in the last 24 hours and down -43.37% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.
See More
Previous Close:
$0.5594
Open:
$0.572
24h Volume:
489.05K
Relative Volume:
0.85
Market Cap:
$9.14M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.6172
EPS:
-0.9111
Net Cash Flow:
$-10.10M
1W Performance:
+2.72%
1M Performance:
-43.37%
6M Performance:
-64.41%
1Y Performance:
-18.80%
1-Day Range:
$0.546
$0.586
1-Week Range:
$0.5324
$0.6033
52-Week Range:
$0.50
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.5623 | 9.09M | 0 | -12.47M | -10.10M | -0.9111 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
HOTH.O - Reuters
Guidance Update: Whats the fair value of Hoth Therapeutics Inc stock2026 Earnings Surprises & Stock Timing and Entry Methods - baoquankhu1.vn
Hoth Therapeutics Completes Registered Direct Offering Financing - The Globe and Mail
Hoth Therapeutics, Inc. (HOTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Hoth Therapeutics, Inc. (HOTH) stock price, news, quote and history - Yahoo Finance UK
Hoth Therapeutics closes $2 million registered direct offering By Investing.com - Investing.com Canada
Hoth Therapeutics announces closing of $2 million registered direct offering - marketscreener.com
Hoth Therapeutics Announces Closing Of $2 Million Registered Direct Offering - TradingView
Hoth Therapeutics Raises $2M in Registered Direct Offering - National Today
Hoth Therapeutics closes $2 million registered direct offering - Investing.com
Hoth Therapeutics Raises $2 Million in Registered Direct Offering; Issues Five-Year Warrants - TradingView
Hoth Therapeutics (NASDAQ: HOTH) closes $2M registered direct stock deal - Stock Titan
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering - PR Newswire
Hoth Therapeutics (NASDAQ: HOTH) raises ~$2.0M; concurrent warrants issued - Stock Titan
Hoth Therapeutics’ HT-001 meets primary endpoint in interim analysis By Investing.com - Investing.com South Africa
Hoth Therapeutics raises $2M in registered direct offering By Investing.com - Investing.com Australia
Hoth Therapeutics raises $2M in registered direct offering - Investing.com
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering - PR Newswire
Hoth Therapeutics’ HT-001 meets primary endpoint in interim analysis - Investing.com
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six - PR Newswire
Hoth Therapeutics receives China patent for mast cell therapy By Investing.com - Investing.com Australia
Energy Moves: Is Hoth Therapeutics Inc stock trending bullish2026 Dividend Review & AI Enhanced Trading Signals - baoquankhu1.vn
Hoth Therapeutics receives China patent for mast cell therapy - Investing.com
Hoth Therapeutics announces issuance of Chinese patent for cancer cell-targeting technology - marketscreener.com
Hoth Therapeutics Announces Issuance Of Chinese Patent For Cancer Cell-Targeting Technology - TradingView
China patent backs Hoth technology designed to kill mast cells - Stock Titan
Moving Averages: Is Hoth Therapeutics Inc a good ESG investment2026 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Hoth Therapeutics 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, FDA Regulatory Pathways, and Risk Factors Overview - Minichart
Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Hoth Therapeutics 10-K: $0 Revenue, $(0.90) EPS, $(12.47)M Net Loss - tradingview.com
Hoth Therapeutics (NASDAQ: HOTH) warns on cash needs and going‑concern risk - Stock Titan
Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Aug Sentiment: Will Hoth Therapeutics Inc stock recover after earningsOptions Play & Weekly Setup with ROI Potential - baoquankhu1.vn
Hoth Therapeutics launches AI platform for drug discovery By Investing.com - Investing.com Canada
Hoth Therapeutics Launches OpenClaw AI for Accelerating Drug Discovery - Contract Pharma
HOTH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hoth Therapeutics Deploys OpenClawtm AI Platform to Accelerate Drug Discovery - Lelezard
Hoth Therapeutics launches AI platform for drug discovery - Investing.com
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery - PR Newswire
EXCLUSIVE: Hoth Therapeutics Targets Faster Drug Discovery With New AI Platform - Benzinga
Hoth Therapeutics (NASDAQ:HOTH) Receives Buy Rating from D. Boral Capital - Defense World
HOTH: Analyst Jason Kolbert Maintains Buy Rating with $5 Target Price | HOTH Stock News - gurufocus.com
Hoth reports positive pharmacokinetic data for topical HT-001 By Investing.com - Investing.com Australia
Hoth reports positive pharmacokinetic data for topical HT-001 - Investing.com
Hoth Therapeutics Reports Positive Ht-001 Pk, Safety, And Clinical Activity Data In Cancer Patients With Egfr Therapy - TradingView
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption - PR Newswire
Hoth Therapeutics stock faces biotech volatility amid pipeline updates and market pressures - AD HOC NEWS
Hoth Therapeutics shares climb after expanding AI partnership with NVIDIA - MSN
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
Fed Meeting: Will Hoth Therapeutics Inc announce a stock splitMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Aug EndMonth: How much upside does Hoth Therapeutics Inc have2026 Setups & Advanced Technical Signal Analysis - baoquankhu1.vn
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):